SBIR/STTR Research Award

Tools to Study Mammalian Mutagenesis

Award identifier cd1b35775c2c6c86541dc61f0b6383e97e490464d258b17f5ed0702e91711d48Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$199,988

Program and phase

SBIR · Phase I

Award year

2012

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Litron Laboratories Ltd
Proposal award date
Not reported
Contract end date
Not reported
UEI
LJH7LE9AUHL5
Solicitation number
PA09-187
Topic code
NIEHS

Research abstract

DESCRIPTION (provided by applicant): Despite the extensive work being performed to understand cancer and carcinogenic properties of chemicals and other agents, there are still gaps in our ability to efficiently identify carcinogens, and elucidate their mode(s) of action. The current state of assays designed to examine mutation and carcinogenic mechanisms are especially limited by their high costs and low throughput capacities. This laboratory has developed a gene mutation assay that is based on the endogenous Pig-a gene. The Pig-a gene product is essential for the biosynthesis of glycosyl phosphatidylinositol (GPI) anchors. Mutations giving rise to nonfunctional GPI anchors prevent certain proteins from being expressed on the cell surface, and this represents a phenotype that can be measured by flow cytometry. The work proposed herein will extend our development efforts by creating a suite of assays that represent a platform for studying a key mode of carcinogenic action, mutation. By devising Pig-a based methods that examine cells in culture, laboratory rodents, and human subjects, a truly comprehensive bridging biomarker will be realized. The bridging capabilities and high throughput nature of the proposed mutation assessment tools will contribute significantly to important areas of research that include academic, regulatory, and industrial settings. PUBLIC HEALTH RELEVANCE: The ability to efficiently and comprehensively study mutation, a key pathway of carcinogenesis, is critical for gaining insight into this complex disease, and for elucidating carcinogens' mode of action. We will develop a suite of complementary assays based on an endogenous reporter gene, Pig-a. An important feature of these assays will be their compatibility with high throughput, automated scoring methods, and their ability to bridge between cells in culture, whole animals models, and humans.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

42 SBIR/STTR records share this UEI (1985–2025). Reported award amounts total $18,400,554. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.